HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease.

AbstractBACKGROUND:
A variable inhibition of erythropoiesis has been reported in uremic patients with renal anemia receiving anti-renin-angiotensin-system (RAS) drugs (angiotensin-converting-enzyme inhibitors, and angiotensin-receptor-antagonists). The time to development of renal anemia before dialysis is still unknown.
METHODS:
A retrospective cohort study (1 to 15 years) on records of 327 out-patients (217 males, 110 females) without anemia and with chronic renal insufficiency (creatinine clearance 16 to 75 mL/min) was conducted to estimate the time to development of renal anemia (Hb < 11.5 g/dL in females and Hb < 12.5 g/dL in men), and the time to decrease of Hb by 1 and 2 g/dL or more, irrespective of anemia development. Two treatment groups were analyzed: 142 patients with, and 185 without anti-RAS drugs.
RESULTS:
Median survival time to development of anemia was 81 months, 59 months to the loss of Hb > 1 g/dL, and 94 months for the loss of Hb > 2 g/dL. Anemia developed significantly earlier in patients with initial Ccr < 40 mL/min and in those with initial Hb < 14 g/dL. In the multivariate analysis (Cox model), male gender, Ccr < 40 mL/min, and Hb < 14 g/dL, in increasing order of relative risk, significantly contributed to prediction of anemia development without any influence of the treatment with anti-RAS drugs. The same results were obtained considering survival to the loss of either Hb > 1 g/dL or Hb > 2 g/dL.
CONCLUSIONS:
Development of renal anemia in mild to severe chronic kidney disease is not influenced by treatment with anti-RAS drugs.
AuthorsAntonio Piccoli, Giordano Pastori, Erika Pierobon, Serena Torraca, Michele Andreucci, Massimo Sabbatini, Bruno Cianciaruso
JournalJournal of nephrology (J Nephrol) 2005 Sep-Oct Vol. 18 Issue 5 Pg. 585-91 ISSN: 1121-8428 [Print] Italy
PMID16299686 (Publication Type: Journal Article)
Chemical References
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
Topics
  • Anemia (chemically induced)
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors (adverse effects)
  • Cohort Studies
  • Erythropoiesis (drug effects)
  • Female
  • Humans
  • Kidney Failure, Chronic (complications)
  • Male
  • Middle Aged
  • Renin-Angiotensin System (drug effects)
  • Retrospective Studies
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: